<!DOCTYPE html>
<!--[if lt IE 7 ]><html class="ie ie6" lang="en"> <![endif]-->
<!--[if IE 7 ]><html class="ie ie7" lang="en"> <![endif]-->
<!--[if IE 8 ]><html class="ie ie8" lang="en"> <![endif]-->
<!--[if (gte IE 9)|!(IE)]><!--><html lang="en"> <!--<![endif]-->
<head>

    <!-- Basic Page Needs
  ================================================== -->
	<meta charset="utf-8">
	<title>Times of Neurology</title>
	<meta name="description" content="Newsletter, Neurology,Epilepsy Designed by Medeka | medekahealth.com">
	<meta name="author" content="Neurology,Epilepsy">
	
    <!-- Mobile Specific Metas
  ================================================== -->
	<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">
    
    <!-- CSS
  ================================================== -->
  	<link rel="stylesheet" href="css/zerogrid.css">
	<link rel="stylesheet" href="css/style.css">
    <link rel="stylesheet" href="css/responsive.css">
	<link rel="stylesheet" href="css/responsiveslides.css" />
	
	<!--[if lt IE 8]>
       <div style=' clear: both; text-align:center; position: relative;'>
         <a href="http://windows.microsoft.com/en-US/internet-explorer/products/ie/home?ocid=ie6_countdown_bannercode">
           <img src="http://storage.ie6countdown.com/assets/100/images/banners/warning_bar_0000_us.jpg" border="0" height="42" width="820" alt="You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today." />
        </a>
      </div>
    <![endif]-->
    <!--[if lt IE 9]>
		<script src="js/html5.js"></script>
		<script src="js/css3-mediaqueries.js"></script>
	<![endif]-->
	
	<link href='./images/ton.ico' rel='icon' type='image/x-icon'/>
    <script src="js/jquery.min.js"></script>
	<script src="js/responsiveslides.js"></script>
	<script>
		$(function () {
		  $("#slider").responsiveSlides({
			auto: true,
			pager: false,
			nav: true,
			speed: 500,
			maxwidth: 962,
			namespace: "centered-btns"
		  });
		});
	</script>
	
	
</head>
<body>
<!--------------Header--------------->
<header>
	<div class="subnav">
		<div class="wrap-subnav zerogrid">
			<div class="links">
				<ul>
					<li><a href="index.html">Home</a></li>
					<li><a href="aboutus.html">About</a></li>
					<li><a href="contact.html">Contact</a></li>
				</ul>
			</div>
		</div>
	</div>
	<div class="wrap-header zerogrid">
		<div id="logo"><a href="#"><img src="./images/logo.png"/></a></div>
</header>

<nav>
	<div class="wrap-nav zerogrid">
		<div class="menu">
	<ul>
		<li><a href="SV.html">Sodium Valproate</a></li>
		<li><a class="current" href="DP.html">Clobazam</a></li>
		<li><a href="OXCB.html">Oxcarbazepine</a></li>
        <li><a href="OXCB_PM.html">Pregabalin</a></li>
        <li><a href="NN.html">Neurology News</a></li>        
	</ul>
		</div>
		
		<div class="minimenu"><div>TOPICS</div>
			<select onchange="location=this.value">
            <option value="index.html">Home</option>
				<option value="SV.html">Sodium Valproate</option>
				<option value="DP.html">Clobazam</option>
           		<option value="OXCB_HM.html">Hospital Coverage </option>     
				<option value="OXCB.html">Oxcarbazepine</option>
                <option value="OXCB_PM.html">Pregabalin</option>
                <option value="EXPO.html">Disease Perspective</option>
                <option value="NN.html">Neurology News</option>
                <option value="quiz.html">Neurology Quiz</option>
			</select>
		</div>
	</div>
</nav>

<!--------------Content--------------->
<section id="content">
	<div class="wrap-content zerogrid">
	  <div class="row">
		  <div id="main-content" class="col-2-3">
            <div class="wrap-col">
					<article>
					 <h2h><a href="DP.html">Clobazam</a></h2h>
                    <br>
					 <ul><li><h2><a href="DP.html">Clobazam: An effective long-term treatment option for lennox Gastaut syndrome</a></h2>
						<span class="info">by medeka healthcare on october 01, 2013</a></span></li></ul>

			  </article>
					<article>
					  <h11>Long-term effects of clobazam in patients with LGS</h11>
						<p><h11b>Efficacy of clobazam</h11b><br>
                      The OV-1002 and OV-1012 studies demonstrated that
clobazam was well-tolerated and efficacious in the
treatment of drop seizures.<sup><a href="DP-IV.html">4,5</a></sup> Additionally, clobazam
significantly decreased average weekly rates of drop
seizures and total seizures when compared with
placebo.<sup><a href="DP-IV.html">5</a></sup> <p><img src="images/blog06.gif"/></p>In an on-going OV-1004 trial, clobazam
reduced average weekly rate of drop seizures and
total seizures, regardless of duration of treatment.<sup><a href="DP-IV.html">1</a></sup>
The median percentage decreases in average weekly
rate of drop seizures were 71.1% at 3 months
and 91.6% at 24 months, and median percentage
decreases in total seizures were 64.8% at
3 months and 81.5% at 24 months (Figure 1).<sup><a href="DP-IV.html">1</a></sup><img src="images/figure_05.gif"/></p>
                      <h11b>Sustained effect of clobazam</h11b>
                       <p>In the OV-1002 and OV-1012 studies, clobazam was
shown to reduce average weekly drop attacks and total
seizures.<sup><a href="DP-IV.html">4,5</a></sup> These effects were sustained and continued
to improve in the OV-1004. Clobazam sustained the
responder rates (percentage decreases in weekly rate
of drop attacks and total seizures) throughout the
first 2 years of OV-1004 (Table 1).<sup><a href="DP-IV.html">1</a></sup><img src="images/Table_04.gif"/></p>
                       <h11b>Stability of clobazam dosages</h11b>
                      <p>Drugs with a wide spectrum of efficacy are needed to
treat LGS.<sup><a href="DP-IV.html">3</a></sup> The goal of broad-spectrum antiepileptic
drugs is to limit or delay the need for polytherapy.
However, in most patients, more than one antiepileptic
drug is needed because of the resistant nature and
heterogeneity of LGS.<sup><a href="DP-IV.html">1</a></sup> In the OV-1004 trial, clobazam
dosage stability was carefully monitored as patients
with LGS usually need polytherapy. It was found that
clobazam was generally stable and remained well less
than 2 mg/kg for most patients at the interim cutoff.<sup><a href="DP-IV.html">1</a></sup></p>
                      <h11b>Tolerability of clobazam</h11b>
                      <p>Patients receiving 1,4-benzodiazepines can often
develop drug tolerance.<sup><a href="DP-IV.html">6</a></sup> Development of tolerance
in the OV-1004 trial was not a significant factor for
researchers because: no reduction in response rates
was observed during the first 2 years of the study;
mean modal clobazam dosages did not increase with
time (Table 2); about 80% of patients remained in
long-term treatment; and in some patients a trend
toward a decrease in the number of concomitant
epilepsy treatments was observed.<sup><a href="DP-IV.html">1</a></sup></p><img src="images/Table_05.gif"/>
<h11b>Effect of clobazam on patient’s quality of life</h11b>
                      <p>In patients with LGS, complete remission is not
considered a realistic treatment.<sup><a href="DP-IV.html">7</a></sup> Instead, patient’s
quality of life is considered more important.
According to global evaluations by physicians,
caregivers and patients in the OV-1004 trial,
treatment with clobazam improved the quality of life
of most patients.<sup><a href="DP-IV.html">1</a></sup> Most of the patients were ‘very
much improved’ or ‘much improved’ at all time
points. Additionally, 80% retention rate in the first
2 years indicated overall treatment satisfaction and
therapy compliance for most patients.<sup><a href="DP-IV.html">1</a></sup></p>

<h11b>Safety profile of clobazam</h11b>
                      <p>LGS requires lifetime treatment, and most
likely, polytherapy. Hence, it is important that drugs
used for LGS have a favorable long-term safety
profile. Some of the approved treatments such as
felbamate (aplastic anemia) and lamotrigine (serious
rash) can have serious adverse events.<sup><a href="DP-IV.html">1</a></sup> Clobazam
seems to be well-tolerated in the 2-year analysis of
the OV-1004 trial.<sup><a href="DP-IV.html">1</a></sup> <p><img src="images/blog07.gif"/></p>Respiratory infections and falls
are among the most common adverse events reported
with clobazam use; however, adverse effects are
expected in a long-term trial in patients with LGS.
In pediatric patients, upper respiratory tract infection
and pneumonia occurred predominately, which is
quite common in trials involving pediatric patients
with epilepsy. Additionally, no new safety concerns
were reported in the open-label extension trial when
compared with the results of short-term controlled
trials.<sup><a href="DP-IV.html">1</a></sup></p>

			  </article>
					<ul id="pagi">
						<li><a  href="DP-I.html">1</a></li>
						<li><a class="current" href="DP-II.html">2</a></li>
                        <li><a href="DP-III.html">3</a></li>
                        <li><a href="DP-IV.html">4</a></li>

					</ul>
					
		    </div>
            <p><br>
            <div class="featured">
	<div class="wrap-col">
		<div class="slider">
			<div class="rslides_container">
				<ul class="rslides" id="slider">
					<li><img src="images/slide04.jpg"/></li>
					<li><img src="images/slide15.jpg"/></li>
                  
				</ul>
			</div>
		</div>
	</div>
</div>
            
            
	    </div>
			<div id="sidebar" class="col-1-3">
				<div class="wrap-col">
                <div class="box">
					  <div class="heading">
					    <h2>Contents</h2></div>
						<div class="content">
							<div class="linklist">
							  <ul><li><a href="IM.html">Initial monotherapy with levetiracetam fails more
frequently than monotherapy with valproate or
oxcarbazepine:</a>An enlightening evidence</li>
									<li><a href="SVpage_1.html">Sodium valproate:</a>A gold standard for the treatment of
childhood epilepsy</li>
									<li><a href="SVpage_2.html">Superior efficacy of sodium valproate IV reported in</a> acute seizures and status epilepticus</li>
									<li><a href="DP.html">Clobazam: </a>An effective long-term treatment option
for Lennox-Gastaut syndrome</li>
                                    <li><a href="OXCB_HM.html">Hospital coverage:</a>Krishna Institute of Medical Sciences</li>
                                <li><a href="OXCB.html">Oxcarbazepine:</a>A valuable treatment option for
partial-onset seizures in children</li>
                                      <li><a href="OXCB_PM.html">Pregabalin and methylcobalamin combination for
neuropathic pain:</a>The Indian scenario</li>
                                <li><a href="EXPO.html">Important aspects of epilepsy management:</a>during pregnancy</li>
                                    <li><a href="NN.html">Neurology News</a></li>
                                    <li><a href="quiz.html">Neurology Quiz</a></li>
                                    
								</ul>
							</div>
						</div>
				  </div>
                  <div class="box">
						<div class="heading"><h2>News Digest</h2></div>
						<div class="content">
							<div class="posts">
								<img src="images/post01.png"/>
								<h4><a href="#">ECG should be considered
in patients with refractory
epilepsy</a></h4><br>
									<p>Analysis of electrocardiogram
(ECG) monitoring
in patients with refractory
epilepsy revealed significant differences in
heart rate between ictal and pre-ictal states,
between ictal and post-ictal states, and
between pre- and post-ictal states. Hence,
ECG might be helpful to detect serious
cardiac abnormalities in patients with
refractory epilepsy.</p><p class="sideref">J Res Med Sci. 2013;18(Suppl 1):S32–4.</p>
							</div>
							<div class="posts">
								<img src="images/post02.png"/>
								<h4><a href="#">Use of gabapentin in pregnancy is not associated with increased risk of major malformations</a></h4><br>
							<p>A prospective study of
pregnancy outcomes in
223 pregnant women who were exposed to gabapentin and 223 pregnant women who were unexposed to gabapentin reported
that gabapentin use in pregnancy was not associated with increased risk for major malformations.</p> <p class="sideref">Epilepsy Behav. 2013;26(1):109–13.</p>
							</div>
							<div class="posts">
								<img src="images/post03.png"/>
								<h4><a href="#">A portable automatic device for the detection of generalized tonicclonic seizures</a></h4>
							<p>Increased S100B protein levels in cerebrospinal fluid may be associated with the neuronal damage following central nervous infections.</p>
							<p class="sideref">Epilepsia. 2013;54(4):e58–61.</p></div>
						</div>
				  </div>
					<div class="box">
						<div class="heading">
						  <h2>Updates</h2></div>
						<div class="content"> <img src="images/updates_add01.gif"/>						  <img src="images/updates_add02.gif"/>
						</div>
					</div>
				</div>
			</div>
	  </div>
  </div>
</section>
<!--------------Footer--------------->
<footer>
	<div class="copyright">
		<p>Copyright © 2013 Medekahealth.com - All rights reserved. | Design: <a href="http://www.medekahealth.com/">MedekaHealth.com</a><a href=</p>
	</div>
</footer>

</body></html>